Last news
ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease...

MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026

MICROIP to Debut "AI Vehicle System Business Group" and Edge AI Innovations at COMPUTEX 2026

TAIPEI, June 1, 2026 /PRNewswire/ -- MICROIP (TPEx: 7796), specializing in AI software and ASIC design services, will unveil its "AI Vehicle System Business Group" at COMPUTEX 2026 (Booth A1215a, TWTC Hall 1, June 2-5). Echoing the "AI Together"...

ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO

ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO

SUZHOU, China, June 1, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 American Society of Clinical Oncology...

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression . The 3→ 1.5 mg/kg dose group (n=22) showed ORR of 86.4% , confirmed...

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous...

New Taipei City Showcases Smart Manufacturing Strength at AUTOMATE 2026

New Taipei City Showcases Smart Manufacturing Strength at AUTOMATE 2026

Exploring New Business Opportunities with Global Buyers TAIPEI, June 1, 2026 /PRNewswire/ -- The New Taipei City Government is leading a delegation of 20 companies specializing in smart manufacturing, automation, industrial AI, and key components to...

AMD Bundles Carbice Ice Pad with Ryzen™ 7 5800X3D

AMD Bundles Carbice Ice Pad with Ryzen™ 7 5800X3D

The Carbice Ice Pad provides a reliable, peel-and-stick, maintenance-free thermal paste alternative designed for consistent gaming performance over the life of a system Partnership marks the first time consumers can experience advanced carbon...

Carbice and Noctua Partner to Bring Advanced Thermal Pad Technology to DIY PC Builders

Carbice and Noctua Partner to Bring Advanced Thermal Pad Technology to DIY PC Builders

Noctua is the exclusive retail distributor of Carbice® IP90 thermal pads for the DIY PC market, beginning with the NT-CP1 AM5/4 for AMD Ryzen™ processors ATLANTA, June 1, 2026 /PRNewswire/ -- Carbice, a U.S.-based developer and supplier of...

1 2 3 4 5 6 7 8 9 10 ... 4637
menu
menu